Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures used to support application for De Novo classification Second IDE approved for U.S. clinical trial for ...

Johnson & Johnson (JNJ) just made a move that investors have been waiting years to see. The healthcare heavyweight submitted its OTTAVA robotic surgical system to the FDA for De Novo classification.

Johnson & Johnson (JNJ) just made a move that investors have been waiting years to see. The healthcare heavyweight submitted its OTTAVA robotic surgical system to the FDA for De Novo classification.

Johnson & Johnson let Medtronic and Intuitive Surgical know that it still has a seat at the surgical robotics market’s table. The New Brunswick, NJ-based company submitted a de novo request to FDA for ...

(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced the submission of an application to the U.S. Food and Drug Administration, seeking De Novo classification for OTTAVA Robotic Surgical System, a ...

| DelveInsight The surgical robotic systems market is witnessing significant growth, driven by the rising adoption of minimally invasive procedures and the increasing demand for precision and improved ...

Jan 12 (Reuters) - Johnson & Johnson convinced ‌Delaware's highest court to throw out ‌part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a maker of surgical ...

Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification.